MINIPRESS XL Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Minipress Xl, and when can generic versions of Minipress Xl launch?
Minipress Xl is a drug marketed by Pfizer and is included in one NDA.
The generic ingredient in MINIPRESS XL is prazosin hydrochloride. There is one drug master file entry for this compound. Thirty-four suppliers are listed for this compound. Additional details are available on the prazosin hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Minipress Xl
A generic version of MINIPRESS XL was approved as prazosin hydrochloride by TEVA PHARMS on September 12th, 1988.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for MINIPRESS XL?
- What are the global sales for MINIPRESS XL?
- What is Average Wholesale Price for MINIPRESS XL?
Summary for MINIPRESS XL
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 100 |
| Clinical Trials: | 27 |
| Patent Applications: | 2,737 |
| DailyMed Link: | MINIPRESS XL at DailyMed |
Recent Clinical Trials for MINIPRESS XL
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Yale University | Phase 1/Phase 2 |
| University of Washington | Phase 4 |
| Fast Grants | Phase 2 |
US Patents and Regulatory Information for MINIPRESS XL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pfizer | MINIPRESS XL | prazosin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 019775-001 | Jan 29, 1992 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Pfizer | MINIPRESS XL | prazosin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 019775-002 | Jan 29, 1992 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for MINIPRESS XL
International Patents for MINIPRESS XL
See the table below for patents covering MINIPRESS XL around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Argentina | 210937 | PROCEDIMIENTO PARA LA PREPARACION DE LA FORMA ALFA CRISTALINA DE CLORHIDRATO DE 2-(4-(2-FUROIL)PIPERAZIN-1-IL)-4-AMINO-6,7-DIMETOXIQUINAZOLINA | ⤷ Start Trial |
| Australia | 2244377 | ⤷ Start Trial | |
| Australia | 506937 | ⤷ Start Trial | |
| Belgium | 851878 | ⤷ Start Trial | |
| Bulgaria | 29724 | METOD ZA POLUCHAVANE NA KRISTALNA- ALFA- FORMA NA PRAZOSIN KHIDROKHLORID (METHOD FOR OBTAINING OF CRISTAL- ALFA- FROM OF PRAZOCIN HYDROCHLORIDE) | ⤷ Start Trial |
| Canada | 1068269 | FORMES CRYSTALLINES DU CHLORHYDRATE DE PRAZOZINE (CRYSTALLINE FORMS OF PRAZOS IN HYDROCHLORIDE) | ⤷ Start Trial |
| Switzerland | 618436 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch